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doi:10.101Everolimus in Combination with Cyclosporin A as
Pre- and Posttransplantation Immunosuppressive
Therapy in Nonmyeloablative Allogeneic
Hematopoietic Stem Cell Transplantation
Christian Junghanss,1 Susanne Rathsack,1 Rainer Wacke,2 Volker Weirich,3 Heike Vogel,4
Bernd Drewelow,2 Sabrina Mueller,1 Simone Altmann,1 Mathias Freund,1 Sandra Lange1Everolimus (RAD001) is anmTOR inhibitor that has been successfully used as an immunosuppressant in solid-
organ transplantation.Data in allogeneic hematopoietic stemcell transplantation (HSCT) is limited. This study
aimed to investigate pharmacokinetics, safety, and efficacy of RAD001 in a canine allogeneic HSCT model.
First, pharmacokinetics of RAD001 were performed in healthy dogs in order to determine the appropriate
dosing. Doses of 0.25 mg RAD001 twice daily in combination with 15 mg/kg cyclosporin A (CsA) twice daily
were identified as appropriate starting doses to achieve the targeted range of RAD001 (3-8 mg/L) when orally
administered. Subsequently, 10 dogswere transplanted using 2Gy total body irradiation (TBI) for conditioning
and 0.25 mg RAD001 twice daily plus 15 mg/kg CsA twice daily for pre- and posttransplantation immunosup-
pression. Seven of the 10 transplanted dogs were maintained at the starting RAD001 dose throughout the
study. For the remaining 3 dogs, dose adjustments were necessary. RAD001 accumulation over time did
not occur. All dogs initially engrafted. Five dogs eventually rejected the graft (weeks 10, 10, 13, 27, and 56).
Two dogs died of pneumonia (weeks 8 and 72) but were chimeric until then. Total cholesterol rose from
median 4.1 mmol/L (3.5-5.7 mmol/L) before HSCT to 6.0 mmol/l (5.0-8.5 mmol/l) at day 21 after HSCT,
but remained always within normal range. Changes in creatinine and triglyceride values were not observed.
Long-term engraftment rates were inferior to sirolimus/CsA and mycophenolate mofetil (MMF)/CsA
regimen, respectively. RAD001/CsA caused a more pronounced reduction of platelet counts to median
2 109/L (range: 0-21 109/L) and longer time to platelet recovery of 21 days (range: 14-24 days) compared
with MMF/CsA. CsA c2h levels were significantly enhanced in the RAD001/CsA regimen, but c0h and area
under the curve from 0 to 12 hours (AUC0-12h) values did not differ compared with an MMF/CsA immuno-
suppression. In summary, immunosuppression consisting of RAD001 and CsA is well tolerated but not as
efficient as with other established immunosuppressants in a canine nonmyeloablative HSCTregimen. Hence,
our study does not support the application of RAD001/CsA as standard practice in this setting.
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Everolimus (RAD001) is an orally active prolifera-
tion signal inhibitor of themammalian target of rapamy-
cin (mTOR) with immunosuppressive activity. It
interferes with themTORsignaling pathway by inhibit-
ing mTOR phosphorylation activities, thereby halting
the translation of proteins critical for proliferation and
cell survival. It was successfully used alone or in combi-
nation with cyclosporin A (CsA) as an immunosuppres-
sant in solid-organ transplantations [1-3]. Combined
application of RAD001 and CsA resulted in synergistic
immunosuppressive activity that allowed CsA dose
reduction and minimized CsA-related nephrotoxicity.
Comparative analyses revealed that immunosuppression
with RAD001/CsA resulted in equivalent graft survival1061
1062 Biol Blood Marrow Transplant 18:1061-1068, 2012C. Junghanss et al.and rejection rates compared with mycophenolate mo-
fetil (MMF)/CsAafter renal transplantationand in supe-
rior efficacy comparedwith azathioprine/CsA in cardiac
transplant recipients [2,4]. In addition, RAD001
significantly reduced the incidence of viral infections,
particularly cytomegalovirus (CMV), in heart and
kidney transplantation [4,5]. However, RAD001/CsA
administration was associated with increased incidents
of renal dysfunction when used with full-dose CsA,
hyperlipidemia, and thrombocytopenia compared with
MMF/CsA. The exposure-response relationship and
the safety profile determined in solid-organ transplanta-
tions support a therapeutic range of RAD001 trough
level of 3-8 mg/L.
Studies on the application of RAD001 in hemato-
poietic stem cell transplantation (HSCT) are limited.
One study used RAD001 in combination with tracro-
limus as graft-versus-host disease (GVHD)-prophy-
laxis in allogeneic HSCT following busulfan-based
intensive conditioning [6]. This study was prematurely
terminated because of an increased rate of sinusoidal
obstruction syndrome.
Here we asked whether RAD001 can be combined
with CsA as pre- and posttransplantation immunosup-
pression in a nonmyeloablative HSCT setting. There-
fore, we investigated the pharmacokinetics as well as
the efficacy and safety of a combined immunosuppres-
sion consisting of RAD001 and CsA after a 2 Gy total
body irradiation (TBI) conditioning in a canine alloge-
neic HSCT model.MATERIALS AND METHODS
Laboratory Animals
Litters of random-bred beagles were purchased
from commercial kennels licensed by the district ad-
ministration of the county of Paderborn. All dogs
were routinely dewormed and obtained standard im-
munization against rabies, parainfluenza, leptospirosis,
distemper, hepatitis, and parvovirus. Furthermore,
custom-prepared canine papilloma virus vaccine was
given. This study was approved by the review board
of the State Institute for Agriculture, Food Safety
and Fishery Mecklenburg-Vorpommern, Germany.
Dog leukocyte antigen (DLA)-identical donor/
recipient sibling pairs were selected on the basis of
matching for highly polymorphicDLA class I and class
II microsatellite markers and DLA-DRB1 single-
strand conformation polymorphism analysis [7,8]. At
study entry, dogs weighed a median of 12.5 kg
(range: 9.8-14.6 kg) and were a median of 16 months
(range: 11-29 months) old.
Pharmacokinetic Assessment
Pharmacokinetic studies targeted at RAD001
trough levels in the range of 3-8 mg/L as recommendedin solid-organ transplantations.Therefore, healthy dogs
were given doses of 1.5, 0.5, and 0.25 mg of RAD001
twice daily orally alone and in combination with 15
mg/kg CsA twice daily orally for 5 consecutive days.
At day 5, serial EDTA-blood samples were collected
for full (9-point) pharmacokinetic studies before and
0.5, 1, 1.5, 2, 3, 4, 6, and 12 hours after the morning
dose and stored at 220C. To exclude an effect of
food on RAD001 absorption, dogs had an overnight
fast before pharmacokinetic analyses and continued to
fast for 4 hours afterRAD001morning dose application.
Whole-blood concentrations of RAD001 were deter-
mined by fluorescence-polarization-immunoassay with
a TDx/FLx analyzer (Abbott Laboratories, Abbott
Park, IL) using a RAD001-specific monoclonal anti-
body (Innofluor Certican Assay System; Seradyn
Inc., Indianapolis, IN). A noncompartmental analysis
(KINETICA 4.4; Thermo Fisher Scientific Inc.,
Waltham, MA) was used to calculate the maximum
concentration (Cmax), time to reach maximum concen-
tration (Tmax), and half-life as well as the area under
the curve over the 12-hour dosage interval (AUC0-12h).
Pharmacokinetic profiles of transplanted dogs
were similarly assessed on days 5 and 21 after
HSCT. In addition, whole-blood concentrations of
CsA were analyzed in parallel with the RAD001 phar-
macokinetics in healthy dogs and after HSCT by
a fluorescence-polarization-immunoassay (TDx/
TDxFLxCyclosporinmonoclonal [whole-blood] as-
say, Abbott Laboratories) with a TDx/FLx analyzer.
CsA AUCwere estimated using the following equation
developed by Novartis for renal transplant patients:
AUC 5 990 1 [10.74  c0h] 1 [2.28  c2h]. Several
full pharmacokinetics of CSA were recorded as well
to prove the applicability of this formula in the canine
HSCT model.HSCT
Dogs (n5 10)were administered 2GyofTBIdeliv-
ered at a dose rate of 0.25 Gy/min from a high-energy
linear accelerator (Siemens Primus; 10 MV X-ray).
Bone marrow of DLA-identical littermates was col-
lected under general anesthesia from the humeri, fem-
ora, and iliac crest. Taking into account animal
protection aspects, we reduced the number of required
animals by using 5 donors that were sensitized to the re-
cipient by a previousHSCT inwhich rejectionoccurred
(Table 1). Marrow grafts contained a median of 3.6 
108 total nucleated cells per kg (range: 1.9-11.8  108
total nucleated cells/kg) andamedianCD341 cell count
of 6.0  106 cells/kg (range: 2.6-18.2  106 cells/kg).
Marrowwas infused intravenouslywithin 24 hours after
TBI. The day of marrow infusionwas designated as day
0. Pre- and posttransplantation-immunosuppression
consisted of 15 mg/kg CsA (Sandimmun Optoral,
Novartis, N€urnberg, Germany) twice a day orally
Table 1. Marrow Grafts from DLA-Identical Donors, RAD001, and CsA Dose Adjustment and Outcome after 2 Gy TBI HSCT
Dog
Marrow Cells Dose Adjustment Max. Donor Chimerism
Rejection
(week)
No Rejection
(week)
TNC
(108/kg)
CD34
(106/kg)
RAD001
(mg bid)
CsA
(mg/kg bid)
Granulocytes
(%, [day])
PBMC
(%, [day])
H6E-5395 11.8 10.3 0.25 15 100 [287] 81 [385] — >65
H6E-5868 7.6 6.7 0.25/0.5‡ 16.5 100 [28] 33 [378] — >64
H6E-5399 6.4 13.7 0.25 15 95 [21] 52 [35] — 8†
H5L-9233 6.2 18.2 0.125 7.5 82 [28] 62 [21] 56 —
H5F-8690* 3.7 8.2 0.25 15 100 [91] 100 [77] — >82
H5F-8686* 3.5 5.3 0.25 15 29 [35] 19 [29] 10 —
H5L-9235* 3.1 3.0 0.25 10 48 [20] 16 [14] 13 —
H6E-5872 2.7 4.0 0.5 7.5 54 [29] 26 [34] 10 —
H6E-5876* 2.2 2.6 0.25 7.5 24 [28] 15 [28] 27 —
H5L-9630* 1.9 3.6 0.25 3.75 100 [70] 100 [77] — >71†
DLA indicates dog leukocyte antigen; TNC, total nucleated cell.
*Dogs received grafts from donors that were sensitized to the recipient by a previous HSCT in which rejection occurred.
†Dogs died at days 60 and 503 with mixed and full donor chimerism at death, respectively.
‡Evening dose only was raised to 0.5 mg.
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Novartis) twice a day orally from day 0 to 127. Doses
were adjusted to reach RAD001 trough levels of 3-8
mg/L. The endpoints of the study were engraftment,
level of chimerism, graft loss, death, and the incidence
of GVHD.
Assessment of Hematopoietic Chimerism
Before and after HSCT peripheral blood of the re-
cipients was obtained weekly up to day 77 posttrans-
plantation and in larger intervals thereafter.
Granulocyte and peripheral blood mononuclear cell
(PBMC) fractions were separated by standard Ficoll-
Hypaque density gradient centrifugation (density
1.074 g/mL). Donor/recipient chimerism was also as-
sessed from bone marrow samples aspirated at days 0,
14, 28, 56, and 140 after HSCT. Genomic DNA of pe-
ripheral blood cell fractions and unfractionatedmarrow
were isolated (Nucleobond CB 100; Macherey-Nagel,
D€uren, Germany). Tetranucleotide repeats that were
polymorphic between donors and recipients were am-
plified and quantified as described previously [9].
Toxicity
Toxicity was evaluated from day 0 to day 35 (time
of drug administration) after HSCT by assessment ofTable 2. Steady-State Pharmacokinetic Parameters of RAD001 ± C
Doses* c0h (mg/L) cmax (mg/L) tmax (h)
1.5 mg RAD001 alone (n 5 4) 6.2 (4.8-13.1) 16.2 (12.6-27.1) 1.5 (1.0-1.5
1.5 mg RAD001 + CsA (n 5 2) 28.7 (24.1-33.4) 77.2 (76.7-77.6) 2.3 (1.5-3.0
0.5 mg RAD001 + CsA (n 5 2) 14.5 (14.1-14.9) 22.1 (16.8-27.5) 3.0 (2.0-4.0
0.25 mg RAD001 + CsA (n 5 2) 6.6 (5.5-7.7) 11.7 (9.4-14.0) 2.8 (1.5-4.0
Half-life indicates elimination half-life.
Data are presented as medians (ranges).
*CsA was given at a constant dose of 15 mg/kg. Indicated doses of RAD001 aactivity, defecation, ingestion, and weight loss. Grade
of activity and ingestion was determined according to
the following score: grade 0 5 normal, grade 1 5 re-
duced, grade 25 no activity or ingestion, respectively.
Defecation was graded as follows: grade 0 5 normal
stool, grade 1 5 loose stool, grade 2 5 diarrhea,
grade 3 5 bloody stool. The grading of weight loss
was established according to the following criteria:
grade 0 5 \0.5 kg loss of body weight, grade 1 5
0.5-1.0 kg weight loss, grade 2 5 .1.0 kg weight
loss always in regard to starting weight. Hematologic
toxicities were evaluated by blood cell counts. Leuko-
penia and thrombocytopenia were defined as leukocyte
counts\1.0 109/L and platelet counts\20 109/L.
Furthermore, safety assessment included determina-
tion of laboratory parameters such as blood lipids
and creatinine levels.Statistics
The distribution of data was described using
medians and ranges. Statistical analyses between treat-
ment groups were performed by using the Mann-
Whitney U test. Within the treatment groups, data
of different days were analyzed by the Wilcoxon
matched-pairs signed rank test. Probability of P \
.05 was considered significant.SA in Healthy Dogs
AUC0-12h (mg/L  h) Half-life (h)
Platelet Counts
day 0 day 8
) 117 (96-197) 10.5 (6.2-19.1) 331 (298-352) 242 (195-277)
) 643 (579-707) 11.1 (8.2-14.0) 296 (285-307) 149 (103-195)
) 190 (159-220) 12.5 (10.0-15.1) 328 (308-347) 173 (155-190)
) 97 (85-110) 10.7 (10.0-11.4) 364 (311-416) 223 (179-267)
nd CsA were administered twice daily.
Figure 1. Development of hematopoietic donor chimerism following HSCT (n 5 10). Chimerism was determined within the granulocyte as well as
within the PBMC compartment. - - - no dose adjustment; ,,,,x,,, CsA dose adjustment; –D– RAD001 and CsA dose adjustment.
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RAD001 Pharmacokinetics in Healthy Dogs
RAD001 pharmacokinetics alone or in combina-
tion with CsA were determined in the blood of healthy
dogs in order to establish a suitable dosing scheme for
RAD001 in dogs. The steady-state pharmacokinetic
parameters at different dose levels are summarized in
Table 2.
Initially, 4 dogs received1.5mgRAD001 twice daily
for 5 consecutive days, resulting in amedian trough level
of 6.2ng/mL.Following, dogs received1.5mgRAD001
in combination with CSA to investigate potential phar-
macokinetic interactions. Under this arrangement,
a strong increase in median RAD001 trough levels to
28.7 mg/L was observed. Consequently, RAD001 dose
was titrated down to a final dose of 0.25 mg to achieve
the targeted range of 3-8 mg/L.
Monitoring of the dogs’ blood counts and bio-
chemical parameter on days 0, 5, and 8 did not reveal
any evidence of clinically relevant toxicity. However,
considering all cases regardless of RAD001 dose,
a significant decrease in platelet counts (P 5 .005)
from 316  109/L (285-416  109/L) at day 0 to 195
 109/L (103-277 109/L) at day 8, as well as a signif-
icant increase in cholesterol levels (P5 .008) from 4.5
mmol/L at day 0 to 6.7 mmol/L at day 8 could be0
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Figure 2. Hematologic recovery in dogs after application of a starting dose o
leukocyte and platelet counts after RAD001 treatment (solid line) were compobserved. Both effects seemed to be RAD001 dose
dependent.Engraftment after HSCT
All 10 dogs showed rapid initial engraftment
(Figure 1, Table 1). Five dogs eventually rejected their
grafts and survived with complete autologous recov-
ery. One engrafted dog (H6E-5399) died on day 60
as a result of pneumonia but was mixed chimeric until
then. The 4 remaining evaluable dogs showed sus-
tained chimerism for .64 weeks of follow-up. One
of them (H5L-9630) died because of multiple organ
failure following signs of GVHD (skin change, hair
loss) and pneumonia 72 weeks posttransplantation,
but was full chimeric at that time.
Median maximum PBMC chimerism after
RAD001/CsA treatment amounted to 42% (range:
15-100%) at day 35 (range: 14-385 days). Maximum
granulocyte donor chimerism of median 88% (range:
24-100%) was obtained at day 29 (range: 20-287
days) after HSCT.Hematologic Recovery after HSCT
Hematologic toxicities after HSCT were reflected
by a moderate decrease in leukocytes and a severe dim-
inution of platelets counts (Figure 2).Median leukocyte1
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f 0.25 mg and 15 mg/kg CsA twice a day after HSCT (n 5 10). Median
ared with the MMF-related toxicity (dotted line, historic data [31]).
Table 3. Pharmacokinetic Parameters of RAD001 in Dogs after HSCT
Day c0h (mg/L) cmax (mg/L) tmax (h) AUC0-12h (mg/L  h) Half-life (h)
No RAD001 or CsA adjustment (n 5 4) 5 6.3 (4.0-9.8) 11.6 (7.1-15.0) 2.0 (2.0-2.0) 100 (60-129) 11.6 (11.5-13.9)
21 5.2 (4.0-7.8) 10.4 (9.5-13.0) 1.5 (1.0-4.0) 89 (80-115) 13.3 (12.0-14.3)
CsA adjustment after day 5 (n 5 3) 5 7.9 (6.9-12.0) 15.4 (13.5-15.4) 3.0 (1.0-4.0) 138 (124-154) 13.0 (10.9-14.0)
21 5.3 (4.9-7.4) 10.8 (9.3-13.6) 1.5 (1.5-1.5) 92 (85-113) 11.7 (10.2-22.5)
RAD001 and CsA adjustment after day 5 (n5 3) 5 2.3 (2.0-11.7) 6.3 (5.9-17.3) 2.0 (1.0-3.0) 46 (40-165) 6.2 (5.3-16.8)
21 5.7 (4.6-8.6) 7.5 (7.0-13.4) 3.0 (1.5-6.0) 72 (67-129) 7.5 (6.7-25.5)
All cases (n 5 10) 5 7.2 (2.0-12.0) 13.6 (5.9-17.3) 2.0 (1.0-4.0) 123 (40-165) 11.6 (5.3-16.8)
21 5.5 (4.0-8.6) 10.4 (7.0-13.6) 1.5 (1.0-6.0) 89 (67-129) 12.5 (6.7-25.5)
Half-life indicates elimination half-life.
Data are presented as medians (ranges).
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109/L) to 1.6  109/L (range: 0.7-3.2  109/L) at day
8 (range: 6-11 days). A total of 8 of 10 dogs never
became leukopenic.The remaining2dogshadamedian
duration of leukopenia of 1.5 days (range: 1-2 days) and
amedian time to leukocyte recovery of 9 days (range: 9-
9 days).Median platelet levels were 310 109/L (range:
264-437  109/L) before HSCT and platelet nadirs
amounted to 2  109/L (range: 0-21  109/L) at day
11 (range: 10-14 days) posttransplantation. Thrombo-
cytopeniawasdetected in9of 10dogswith amediandu-
ration of 11 days (range: 2-15 days). Time to platelet
recoverywas 21days (range: 14-24days). Six animals re-
ceived prophylactic transfusions of whole blood or
platelet enriched plasma.
Pharmacokinetics after HSCT
Based on the pharmacokinetics in healthy dogs,
a RAD001 dose of 0.25 mg twice a day (days 0 to
127) was administered in combination with 15 mg/
kg CsA twice a day (days 21 to 135) as pre- and
posttransplantation-immunosuppression in HSCT.
Seven of the 10 transplanted dogs were maintained
at the starting RAD001 dose of 0.25 mg twice daily
throughout the study period. For 1 dog, the dose had
to be reduced. The remaining 2 dogs needed a dose0
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Figure 3. Whole-blood concentration-time profiles of RAD001 in dogs start
displayed. Full pharmacokinetic analyses were done at days 5 and 21 after HSC
partially necessary to achieve the targeted range of 3-8 mg/L. - - - no dose a
dose adjustment.increase to achieve the targeted range (Table 1). Data
of pharmacokinetic analyses after HSCT are summa-
rized in Table 3 and Figure 3. After dose adjustment,
RAD001 trough concentrations reached the targeted
range in all dogs, shown at day 21 posttransplantation.
In 3 of the 7 dogs in which the RAD001 dose was not
changed, CsA dose was diminished leading to a con-
comitant reduction in RAD001 exposure. Comparison
of pharmacokinetic parameters at days 5 and 21 at con-
stant RAD001 and CsA doses (n 5 4) revealed no evi-
dence of drug accumulation over time.
In parallel to RAD001 pharmacokinetics, CsA
whole-blood concentrations were determined in non-
myeloablative transplanted dogs at days 5 and 21 after
HSCT. CsA AUC were generally calculated from ab-
breviated kinetics (c0h, c2h). To prove the applicability
of this method in our canine HSCT model, compari-
sons with AUC values determined from full pharmaco-
kinetics (n 5 9) were conducted. Median AUC levels
of 12,310 mg/L  h (range: 8736-24,683 mg/L  h)
estimated from abbreviated kinetics and 12,439
mg/L  h (range: 9485-25,540 mg/L  h) determined
from full kinetics showed a good comparability of
both methods (P 5 .314).
If healthy dogs (n 5 6) were compared with trans-
planted animals (n 5 10), no significant differences in0
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ing with 0.25 mg RAD001 and 15 mg/kg CSA twice a day after HSCTare
T. In dependence of blood trough levels at day 5 dose adjustment was
djustment; ,,,,,x,,,, CsA dose adjustment; –D–RAD001 and CsA
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Data obtained at different times after HSCT at a con-
stant CsA dose revealed no evidence for CsA accumula-
tion at day 21 compared with day 5 (n 5 4). Median
c0h and c2h values were determined to be 550 mg/L
(range: 236-2237 mg/L) and 3264 mg/L (range:
1955-5486 mg/L). The respective AUC0-12h was
median 13,725 mg/L  h and ranged from 8736-
36,642 mg/L  h.
Toxicity
Biochemical analyses revealed no changes in creat-
inine and triglyceride values during the time of drug
administration. Total cholesterol significantly rose
from a median baseline of 4.1 mmol/L (3.5-5.7
mmol/L) before HSCT to 6.0 mmol/L (5.0-8.5
mmol/L) at day 21 after HSCT. However, these
changes always remained within normal range and
were reversible, because cholesterol values reached
base values (as before HSCT) 15 days after RAD001
was withdrawn.
Evaluation of regimen toxicity was further done for
the parameters activity, defecation, ingestion, and
weight loss. In every dog, gastrointestinal toxicities
were temporarily observed that were characterized
mainly by loose stools and less frequently by diarrhea
and bloody stools. While on treatment, dogs experi-
encedmild effects on activity and ingestion that resulted
in weight loss.0.5 kg in 3 dogs (range: 0.7-1.8 kg).DISCUSSION
In recent years, RAD001 has been successfully
used as an immunosuppressant mainly in kidney and
heart transplantation. Because of these positive experi-
ences, further studies were initiated to investigate
RAD001 in other areas of transplantation. This study
aimed to determine pharmacokinetics, safety, and effi-
cacy of RAD001 in a preclinical HSCT model.
The pharmacokinetic analyses of oral RAD001
monotherapy in healthy dogs revealed comparable
cmax and AUC values to healthy human volunteers. In
several single-dose studies, RAD cmax values in the
range of 15-21 mg/L and AUC values in the range of
90-115 mg/L  h have been reported [10,11]. In
contrast, RAD001 seems to have a considerably
shortened half-life of 12 hours in dogs compared with
24-32 hours in humans [10-12]. However, in dogs
given 1.5 mg RAD001 twice daily, a trough level of
3-8 mg/L can be easily achieved. Interactions of
RAD001 and CsA were investigated in healthy dogs,
because both drugs are metabolized primarily by
CYP3A isoenzymes and are substrates for the
P-glycoprotein efflux transporter. The concomitant
administration of 15 mg/kg CsA twice daily increased
the steady-state parameter of RAD001 cmin, cmax, andAUC 5- to 6-fold in our studies. An enhancement of
RAD001 exposure was also demonstrated in clinical
studies in healthy volunteers [13] and transplant pa-
tients [14,15] when dosed with CsA. In these studies,
CsA caused a 2- to 3-fold increase in RAD001 expo-
sure. The more pronounced effect in our dogs might
be related to the high CsA levels observed, which could
intensify the influence of CsA on RAD001. A 6-fold re-
duction of RAD001 dose in healthy dogs that received
concomitantly CSA allowed the achievement of tar-
geted RAD001 levels that were otherwise achieved us-
ing 1.5 mg RAD001 twice daily alone. This confirms
the dose-proportionality of RAD001 described in pre-
vious clinical studies [16].
For the first time, RAD001 pharmacokinetic anal-
yses were also conducted after HSCT. Irradiation con-
taining conditioning is known to damage oral and
intestinal mucosa and may affect drug absorption.
However, the pharmacokinetic profiles determined
5 and 21 days after HSCT did not differ from parame-
ters identified in healthy dogs, emphasizing the low
toxicity of 2 Gy TBI. Successful dose adjustment in
dogs was easily feasible as shown by the narrower range
of cmin, cmax, andAUC0-12h at day 21 comparedwith day
5 afterHSCT, respectively. In 3 dogs, CsA dose reduc-
tion resulted in a decreasedRAD001 exposure at day 21
compared with day 5, respectively. This reflects the
strong influence of CsA on RAD001 pharmacokinetics
after HSCT as we already described in healthy dogs.
No drug accumulation over time was observed, sug-
gesting that the steady state of RAD001 was reached
within 5 days. These results are in accordance with
data after solid-organ transplantation [17,18].
To consider possible effects of RAD001 on CsA,
pharmacokinetics assessment of steady-state CsA pa-
rameters were performed. Comparison of CsA levels
with its own historic data in which MMF was coadmi-
nistered to CsA [19] indicate a significant increase in
c2h levels when CsA is combined with RAD001 (P 5
.001), whereas differences between trough levels and
AUC did not reach significance. In most clinical stud-
ies, pharmacokinetics of CsA appear not to be affected
by RAD001 coadministration [18,20,21]. However,
Kirchner et al. [21] observed a nonsignificant 10%
augmentation of CsA AUC after administration of
a single, oral dose of RAD001. In addition, Budde
et al. [20] assumed some minor pharmacokinetic inter-
actions between CsA and RAD001. Results of the
pharmacokinetic analyses of RAD001 obtained in
our canine model indicate a good agreement between
the pharmacokinetic characteristics of humans and
dogs, and confirm the usefulness of the dog as a model
system for pharmacological investigations.
Pre- and posttransplantation immunosuppression
consisting of RAD001 and CsA allowed a rapid hema-
topoietic engraftment in all dogs. However, long-term
chimerism was observed in only 4 of 9 evaluable
Biol Blood Marrow Transplant 18:1061-1068, 2012 1067Everolimus in Nonmyeloablative HSCTanimals (44%). The rate of long-term chimeras was
lower compared with results from other nonmyeloa-
blative studies. Storb et al. [22,23] achieved in series
of experiments long-term engraftment with CsA/
MMF in 11 of 12 dogs (92%). Subsequently, MMF
was substituted by the mTOR inhibitor sirolimus in
the same regimen. Durable engraftment in 5 of 6
dogs (83%) was observed [24].
Several studies in humans have documented that
RAD001 in combination with CsA is effective in pre-
venting graft rejection in solid-organ transplantation
[2,25-27]. Comparative studies demonstrated an
equal efficacy of RAD001 and MMF in preventing
graft loss and acute rejection in renal transplantation
[4,28]. In addition, RAD001 allowed low rejection
rates in heart transplant recipients [2,26]. Effects
were equal or superior to MMF or azathioprine
immunosuppression.
Other clinical studies investigated the use of siroli-
mus following myeloablative HSCT [29,30]. In all
studies, the use of the mTOR inhibitor was effective in
regard to engraftment. However, toxicities were
significant. In conclusion, RAD001 seemed to be
effective in a nonmyeloablative conditioning setting in
regard to short-term engraftment. Nevertheless, the
long-term engraftment rates observed are lower com-
pared with a MMF/CsA- or sirolimus/CsA-containing
regimen.
The most common reported adverse events associ-
ated with RAD001 are leukopenia, thrombocytopenia,
hypercholesterolemia, hyperlipidemia, and/or in-
creased creatinine levels [2,4,27]. Consistent with
these known side effects, RAD001 caused an increase
in cholesterol levels and a significant reduction in
platelet counts in both healthy dogs and transplanted
animals in our study. However, cholesterol generally
did not exceed upper normal limits, and levels were
reversible after drug discontinuation and were not of
clinical relevance. Magnitude and time course of
thrombocytopenia and leukopenia as well as the need
for blood transfusion were similar after RAD001/
CsA and sirolimus/CsA treatment [24]. Compared
with dogs that received nonmyeloablative HSCT
withMMF/CsA, thrombocytopenia after RAD001 ad-
ministration was more pronounced (P 5 .002) and as-
sociated with a longer time to recovery (P # .036).
This observation seems to be attributed to the
platelet-reductive effect of RAD001 already observed
in healthy dogs. The course of leukocyte counts was
comparable to that determined in the historic MMF/
CsA group. Hence, leukocyte reduction was caused
by TBI rather than RAD001. Assessment of the pa-
rameters diarrhea, activity, ingestion, and weight loss
also showed no differences compared with MMF/
CsA [19] and sirolimus/CsA [24] treatment.
In line with our data, Platzbecker et al. [6] observed
in 2 of 24 HSCT patients a significant decrease inplatelet counts after initial engraftment that did not re-
cover until RAD001 was discontinued. In solid-organ
transplantation, the incidence and severity of throm-
bocytopenia was reported to be dose related [3]. Con-
sidering the prolonged time to recovery in dogs after
HSCT and the known exposure-response relationship,
a dose escalation of RAD001 was not intended in the
present study.
The trial by Platzbecker et al. [6] had to be termi-
nated prematurely because of the occurrence of severe
adverse events, mainly sinusoidal obstruction syn-
drome of the liver and transplantation-associated mi-
croangiopathy. Severe side effects that required
premature termination were not apparent in our study,
possibly because of the nonmyeloablative conditioning
and the shorter time course of drug administration.
In conclusion, our data demonstrated that pre-
andposttransplantation immunosuppression consisting
of RAD001 and CsA is feasible in a canine 2 Gy TBI
nonmyeloablative HSCT setting and allows initial en-
graftment in all dogs. However, it is not as effective as
sirolimus/CsA and MMF/CsA regimens in regard to
long-term engraftment induction. The general use of
RAD001/CsAas immunosuppressants therefore cannot
be recommended following nonmyeloablative HSCT.ACKNOWLEDGMENTS
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